Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
10 Sources Therapeutic Goods Administration
While access remains uneven across commercial plans and Medicare coverage for obesity medicines is still limited, CVS decision signals continued normalization of GLP-1 therapies within mainstream pharmacy benefit design and intensifies competition between Lilly and Novo Nordisk for long-term market leadership in obesity careTop of FormBottom of Form Sources CVS brings back coverage for Lilly's obesity drug Zepbound Reuters May 28, 2026 Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge Reuters May 1, 2025
So what are you signing up for
Mack, M
These pharmacies are, again, part of a larger conversation but they are playing a fairly dangerous role in the GLP-1 saga
US$ 25.14
US$ 21.58
US$ 20.26
US$ 27.67
US$ 21.25
US$ 28.59
US$ 27.06
US$ 24.17
US$ 22.11
